An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.
You may also be interested in...
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
Agency reorganizes cancer drug reviews by disease type, while keeping leadership, as expected. After scheduled actions, applications will be migrating to their designated areas within the renamed Office of Hematology and Oncology Products.